CUMULATIVE INDEX 1996

Volume 12

January	MEDICAL ETHICS, pages 1–202
April	TRANSESOPHAGEAL ECHOCARDIOGRAPHY AND INNOVATIVE ECHOCARDIOGRAPHIC TECHNOLOGY, pages 203–501
July	CONTROVERSIES IN CRITICAL CARE MEDICINE, pages 503–770
October	MONITORING CARDIAC FUNCTION AND TISSUE PERFUSION, pages 771–1057

Note: Page numbers of article titles are in **boldface** type.

Abdominal aorta surgery, elective, pulmonary artery catheter in goal-directed hemodynamic therapy for, 786
ABGs. See *Arterial blood gases (ABGs).*
Abscess(es), detection, TEE versus TTE in, 417–418
Acoustic quantification (AQ), 884
Acquired immunodeficiency syndrome (AIDS), in critical care computing, 117
Acquired intracardiac shunts, TEE in, 901–902
Acute physiology and chronic health evaluation (APACHE), in ICU scoring systems effectiveness, 506–507, 516–517
Acute respiratory distress syndrome (ARDS), barotrauma in, incidence, 608–610
  manifestations, 610
  outcome following, 611–612
  risk factors for, 612–613
  treatment, 610
 effects on lung, 627
 ventilatory management in, **603–625**
Adenosine, stress echocardiography with, 431
Admission criteria, in prediction of ICU efficiency with full-time intensivists, 536
Afterload, assessment, of left ventricular function, TEE in, 263–265
  right ventricular, PEEP effects on, 850–852
AIDS. See *Acquired immunodeficiency syndrome.*
Air, as factor in TEE imaging, 236–237
Airway(s), artificial, VILI due to, 605
Alpha blocking agents, for shock, 963–964
Anencephalic organ donation, ethical issues related to, 157–158
Aneurysm(s), aortic, 733–736. See also *Aortic aneurysm.*
  TEE in, 887–890
 atrial septal, assessment, TEE in, 283–284
 sinus of Valsalva, rupture of, shunt due to, 308–310
Angiography, radionuclide, in cardiac function evaluation, 920–922
Annulo-aortic ectasia, aortic aneurysm due to, 734–735
Antibiotic costs, in prediction of ICU efficiency with full-time intensivists, 531–532
Aorta, ascending of, ultrasonic examination, 737
 atherosclerotic, debris from, assessment, TEE in, 284–285
 descending, ultrasonic examination, 738–739
 diseases of, **733–766**
  aortic aneurysm, 733–736
  aortic dissection, 744–747
  aortic trauma, 736–737

Aorta *(Continued)*
TEE in, 887–891
trauma of, 736–737
trauma to, acute, TEE in, 890
ultrasonic examination, 737–744
ultrasonic examination, for aneurysm and trauma, 737–744
Aortic aneurysm, 733–736
causes, 734–736
defined, 733–734
TEE in, 887–890
ultrasonic examination, 737–744
Aortic arch, ultrasonic examination, 737–738
Aortic dissection, 744–747
assessment, echocardiography in, 747–760. See also *Echocardiography, in aortic dissection assessment.*
causes, 745–746
classification of, echocardiography in, 757
defined, 744–745
pathophysiology, 746–747
TEE in, 887–890
Aortic insufficiency, echocardiography in aortic dissection for detection of, 759
Aortic prostheses, assessment, TEE in, 392–397
Aortic regurgitation, 364–367
assessment, echocardiography in, 364–367
surgery for, 367–369
Aortic root, ultrasonic examination, 737
Aortic stenosis, 354–364
assessment, echocardiography in, Doppler, 360–364
two-dimensional, 356–360
described, 354–356
Aortic valve, described, 352–354
pseudomasses of, TEE of, 240, 243
TEE of, 352–369
APACHE, in ICU scoring systems effectiveness, 506–507, 516–517
Appetite suppression, in critically ill patients, 672
Argument, role in ethical medical decision making, 73
Arterial blood gases (ABGs), measurement of, **865–874**
continuous, 867–873
advantages of, 868
future of, 872–873
intermittent, 866–867
performance criteria, 868–872
Arterial resistance, measurement of, 828–830
Artery(ies), intravascular ultrasound characteristics of, 454–457
Ascending aorta, ultrasonic examination, 737
Atherosclerosis, of the aorta, 735
Atherosclerotic debris, assessment, TEE in, 284–285
embolism due to, TEE for, 890–891
Atherosclerotic plaque, intravascular ultrasound characteristics of, 457–459
Atria, pseudomasses of, TEE of, 238–240
Atrial fibrillation, assessment, TEE in, 275–276
Atrial septal aneurysm, assessment, TEE in, 283–284
Atrial septal defects (ASDs), 301–305
assessment, contrast studies in, 302–303
Doppler studies in, 303
cardiac output effects of, 305
pressure gradients in, 303–305
quantification of shunts, 305
types, 301–302
Atrial septum, pseudomasses of, TEE of, 238, 240, 241
Automatic border detection, of endocardial borders, 472–478
ultrasonography in, 437–440
Autonomy, 11–12, 135
in physician–patient relationship, 184–185

Bacteriologic safety, with TEE, 238
Barotrauma, in ARDS, incidence, 608–610
manifestations, 610
outcome following, 611–612
risk factors for, 612–613
treatment, 610
pulmonary, forms of, 628–629
ventilator-induced, 607–613, 628–630
pathophysiology, 607
Beneficence, 135
Best interest standard, ethical issues related to, 153–161
experimental or futile care, 160–161
Bicarbonate, gut partial pressure of, assumptions related to, 592
Bioethics, in ICU, **15–27**
in physician–patient relationship, 185–186
Bioethics committee, 21
Bioprostheses, pericardial, assessment, TEE in, 390
porcine, assessment, TEE in, 390
Björk-Shiley prosthesis, TEE in, 386–389
Blood gas monitoring, **865–874**
$Paco_2$, 865–866
Pao_2, 866
Blowing the whistle, 129–131
Breadloafing, in data acquisition for three-dimensional imaging, 480–481
Bronchi, air-filled, as factor in TEE imaging, 237

Burn injuries, in critically ill patients, 670

Carbon dioxide, gut partial pressure of, assumptions concerning, 589–592
Cardiac function, assessment, echocardiography in, 919–920
  gated perfusion imaging in, 927–935
  MRI in, 922–927
  new imaging techniques for, **919–937**
  nuclear techniques in, 920–922
Cardiac index, oxygen delivery and consumption versus, **995–1006**
Cardiac output, 996–998
  adequacy of, defined, 800
  atrial septal defect effects on, 305
  by Fick principle, 810–811
  continuous, right ventricular ejection fraction and, **795–818**
  determination of, TEE in, 260–261
  direct Fick measurements of, in shock, 941
  increase in, in aneurysmal subarachnoid hemorrhage, 722–723
  indicator dilution and thermodilution techniques for, 941
  measurement of, 811–813
    continuous, 810–813
    conventional cardiologic approach to, 942
  noninvasive monitoring of, 959–960
Cardiac surgery, pulmonary artery catheter in goal-directed hemodynamic therapy for, 787–788
Cardiac tamponade, assessment, TEE in, 265–268
Carpentier-Edwards valve, assessment, TEE in, 390
Catheter(s), oximetric, versus pulmonary artery catheters, in goal-directed hemodynamic therapy, 789
  pulmonary artery. See *Pulmonary artery catheter.*
  Swan-Ganz. See *Pulmonary artery catheter.*
CDI–3M Healthcare sensors, in ABG measurements, 869–871
Cerebral ischemia, hypervolemia and hemodilution in, 699–700
Chaplain, hospital, perspective of, 17–18
  roles of, 16
    effects of, 20
    ministry to patients and families, 18–19
    ministry to physicians, 19–20
    ministry to staff, 19
  training process of, 17
Children, critical care for, ethical issues related to, **149–164**
  best interest standard, 153–161
  children whose parents have religious objections to treatment, 158–160
  conflicts between children, 157–158
  rational parent standard, 153–156
  surrogacy, 153–161
Cine-loop digitalization, 884
Circulatory function, oxygen metabolism related to, 952–953
Communication, in resolving medical futility, 170–177
Competence, 8–9
Competency, resolving of, in physician–patient relationship, 152
  legal issues related to, 151–152
Confidentiality, in critical care computing, 116–120
  physician, in critical care computing, 119–120
Conflict of interest, ethics consultation and, 21–22
Confusion, medical futility due to, 173–174
Congenital intracardiac shunts, TEE in, 901–902
Consent, informed. See *Informed consent.*
Consultation, ethics, **49–70.** See also *Ethics consultation; Hospital ethics committees.*
Contrast echocardiography, **440–446,** 883
Coronary artery(ies), involvement in echocardiography in aortic dissection, 758–759
Coronary artery fistulas, 310–313
Cost(s), antibiotic, 531–532
  hospital, in prediction of ICU efficiency with full-time intensivists, 529–531
Critical care computing, ethical issues in, **109–122**
  appropriate use of, 120–121
  computing outcomes, 110–116
    induction and statistics, 110–112
  empiric factors, 112–114
  HIV and AIDS information, 117
  privacy, confidentiality, and electronic patient record, 116–120
  usefulness of predictor models, 114–116
Critical care nurses, ethical dilemmas facing, **123–133.** See also *Ethical issues, facing critical care nurses.*
Culture, hospital, and spirituality, 15–16

Death, beliefs that prolong, 24–26
  critical terms relating to, 4–12
  culture of, 20–21
  determination of, and organ procurement, 32
  ethically based medical decision making in, **71–84**
    role of argument in, 73

Death *(Continued)*
role of disagreement in, 74
role of physician comfort in, 74–75
teaching program for, 75–81
uncertainty in, 74
ethics consultation in, 63–67
good, 4–5
imminent, 8
language of, **1–14**
physician leadership responsibility in, 2
physician responsibilities in, philosophic reflection on, 71–72
spiritual issue and bioethics in, **15–27.** See also *Spiritual issues, in ICU.*
uncertainty regarding, 3–4
Death recognition, 128–129
Deciding to Forego Life-Sustaining Treatment, 49, 136
Decision making, shared, in physician–patient relationship, 192–194
Derivation of pressure half-time, in mitral stenosis assessment, 331
Diastolic dysfunction, assessment, TEE in, 255–258
TEE in, 883–884
Dipyridamole, stress echocardiography with, 431–432
Disagreement, in ethical medical decision making, 74
Discharge criteria, in prediction of ICU efficiency with full-time intensivists, 536
Diuretic(s), dopamine, 690–691
Do_2, 998
determination and relationship in, 998–999
Dobutamine, stress echocardiography with, 432–434
Doctrine of double effects, 126–128
Dopamine, acute renal failure due to, 688–690
as diuretic, 690–691
potential harmful effects, 691–692
renal dose, physiology of, 687–688
protective or therapeutic quality of, affirmative view, **677–685**
negative view, **687–695**
Doppler echocardiography, and infectious endocarditis, 422–423
color-flow, TEE versus, 247–250
in aortic stenosis assessment, 360–364
in atrial septal defect evaluation, 303
in mitral regurgitation assessment, 339–344
in mitral stenosis assessment, 328–330
in prosthetic heart valve assessment, **383–409**
Double effects, doctrine of, 126–128
practice of, 7
Double occlusion technique, for measurement of Pcap, 826
Dysoxia, concept of, 1036–1038

Echocardiography, automatic detection of, data acquisition for, 479–483
breadloafing, 480–481
restricted motion scanning techniques, 480–481
unrestricted scanning techniques, 482–483
contrast, **440–446,** 833
Doppler. See *Doppler echocardiography.*
future of, 877
in abscess detection, 417–418
in aortic dissection assessment, 747–760
aims of, 748–757
diagnostic strategies, 760
for differentiation of true and false lumen, 749–753
for intramural hematoma, 753
for intramural hemorrhage, 753
for localization of intimal tears, 753–754
in aortic insufficiency, 759
in classification of aortic dissection, 757
in coronary artery involvement, 758–759
in differentiation of communicating and noncommunicating dissection, 754–757
in fluid extravasation, 759–760
side branch involvement in, 757
in aortic regurgitation assessment, 364–367
in automatic detection of endocardial borders, 472–478
in cardiac function evaluation, 919–920
in endocarditis assessment, **411–427.** See also *Endocarditis, assessment, TEE in.*
in infectious endocarditis assessment, 418–420
in mitral regurgitation assessment, 337–344
in mitral stenosis assessment, 324–327
in vegetation detection, 414–416
stress, **429–436,** 882–883
three-dimensional, 478–491
assembly and display of, 484–489
clinical applications, 490–491
future direction, 491
qualitative, 490
quantitative, 490–491
reconstruction with, **471–495**
transesophageal, **875–918.** See *Transesophageal echocardiography (TEE).*
transthoracic. See *Transthoracic echocardiography (TTE).*

two-dimensional, in aortic stenosis assessment, 356–360
in mitral stenosis assessment, 324–327
interrelated images, preparatory processing of, 483–484
Echo-free spaces, TEE of, 246–247
Ectasia, annulo-aortic, aortic aneurysm due to, 734–735
Edema, pulmonary, oncotic pressure and, 822–823
Pcap and, 820–823
Education, of hospital ethics committee, 54–55
Effusion, pericardial, TEE in, 885–886
Elective ventilation, 40
Electrical safety, with TEE, 237–238
Electrochemical sensors, in ABG measurements, 867
Electronic array transducers, 453
Embolism. See also specific types.
aortic, mortality due to, 273
assessment, TEE in, **273–294**
atherosclerotic debris and, TEE for, 890–891
in infectious endocarditis, assessment, TEE in, 279–280
paradoxical, stroke due to, patent foramen ovale and, 298–299
pulmonary, assessment, TEE in, 285–287
systemic, assessment, TEE in, 274–285
Endocardial borders, automatic detection of, by integrated backscattering, 473–478
echocardiography in, 472–478
underlying principles, 472
Endocarditis, Doppler echocardiography and, 422–423
infectious, assessment, TEE in, **411–427**
approach to, 424–425
false-positive findings by, 421–422
negative predictive value in, 420–421
described, 411–412
diagnosis, 412–414
embolism in, assessment, TEE in, 279–280
prognosis, echocardiography in, 418–420
prosthetic valve, assessment, TEE in, 416–417
treatment, 411
TEE in, 896–898
Enteral nutrition, in critically ill patients, 668–669, 672–673
Ethic(s), as sustained inquiry, 72
concerns related to, dealing with, 22–26
identification of, 22–26
consultation for, and conflict of interest, 21–22
defined, 72–73
described, 124–125
in ICU, teaching of, 75–81
in physician–patient relationship, **179–197**
medical decision making and, relationship between, 73
of living wills, 191–192
of resuscitation, **135–148**
determining level of treatment at admission, 139–140
Ethical issues, facing critical care nurses, **123–133**
analysis of, 131
implications of, 132
narratives of, 126–131
recognizing death before doctor: death recognition, 128–129
sharing experience of death: doctrine of double effects, 126–128
truth-telling: blowing the whistle, 129–131
in critical care computing, **109–122.** See also *Critical care computing, ethical issues in.*
in neonatal and pediatric critical care. See also under *Children; Neonates.*
in organ procurement, **29–48.** See also *Organ procurement, ethical issues in.*
Ethics committees, hospital, **49–70.** See also *Ethics consultation; Hospital ethics committees.*
Ethics consultant, as arbitrator and communicator, 62–63
Ethics consultation, **49–70.** See also *Hospital ethics committees.*
calling a consultation, 59–60
dealing with the sovereignty of physician practice, 61
in ICU, 63–67
modes of consult initiation and recommendation, 56–58
preparing and charting of, 60
quality of, assessment, 67
team in, 56–63
composition of, 58
Eustachian valve, membranes of, TEE of, 244, 246
Euthanasia, 4–5, **85–96**
history of, 85–87
in the Netherlands, **97–108**
ambivalence of moral justification, 100–103
culture of death, 103–105
historical background, 98–99
medical practice of, 99–100
possibility versus impossibility of public control related to, 105–106
recent developments and debate related to, 87–93
Euthanatos et mors, **1–14**

Evidence-based medicine, emphasis of, 779
Extracardiac fluid, TEE and, 249–250

Family, approach to, in organ procurement process, 33–35
Fan-like scanning, in data acquisition for three-dimensional imaging, 481
Fick method, direct, of cardiac output and Vo_2, in shock, 941
Fick principle, continuous cardiac output by, 810–811
Fistula(s), 308–313
  coronary artery, 310–313
Fluid extravasation, echocardiography in aortic dissection for detection of, 759–760
Fossa ovalis, valve of, membranes of, TEE of, 244, 245
Fracture(s), hip, pulmonary artery catheter in goal-directed hemodynamic therapy for, 786
Fulminius Minor, 553
Futility, 9–11
  defined, 165
  medical, **165–178.** See also *Medical futility.*
  qualitative, 167–168
  quantitative, 166

Gastrointestinal tract, monitoring of, necessity of, 574
Gated blood pool scanning, in cardiac function evaluation, 920–922
Gated perfusion imaging, in cardiac function evaluation, 927–935
Ghosting, TEE and, 248–249
Global systolic function, assessment, TEE in, 258–260
  evaluation, index for, 878–879
Glucose, in critically ill patients, 673
Glutamine, in critically ill patients, 664–665
Glycolysis, generation of energy via, 1033–1035
Good death, 4–5
Gorlin equation, 324
Guidelines on the Termination of Life-Sustaining Treatment and the Care of the Dying, 136–137

Hancock valve, assessment, TEE in, 390
Health-care technology, evaluation, approaches, 778–779
Hematoma(s), intramural, echocardiography in aortic dissection for detection of, 753
Hemodilution, hypervolemia, and hypertension, 701–703
  in cerebral ischemia, 699–700
Hemodynamic monitoring, criteria for, 774
  history of, 795–796
  interpretation of, PEEP effects on, 855–861
Hemodynamic monitoring systems, advantages of, noninvasive, 959
Hemodynamic therapy, goal-oriented, 781–786
Hemorrhage, intramural, echocardiography in aortic dissection for detection of, 753
Hernia(s), hiatal, TEE of, 246–247
Hiatal hernia, TEE of, 246–247
High-inflation pressure, extrapulmonary effects, 632–633
  lung injuries due to, **603–625, 627–634**
Hip(s), fracture of, pulmonary artery catheter in goal-directed hemodynamic therapy for, 786
HIV. See *Human immunodeficiency virus.*
Hospital charges, in prediction of ICU efficiency with full-time intensivists, 529–531
Hospital culture, and spirituality, 15–16
Hospital ethics committees, **49–70**
  calling a consultation, 59–60
  composition of, 50–52, 58
  education of, 54–55
  function of, 50
  leadership of, 52
  modes of consult initiation and recommendation by, 56–58
  position within hospital's political environment, 52–54
  resolving physician conflicts by, 61–62
  role of, 55–56
Human immunodeficiency virus (HIV), in critical care computing, 117
Hypercapnea, permissive, in prevention of VILI, 619
Hypertension, hypervolemic, hemodilutional therapy, 701–703
  for aneurysmal subarachnoid hemorrhage, affirmative view, **697–707**
    basis for skepticism, 710–711
    complications, 723–724
    CVP monitoring of, 721–722
    efficacy of, 711–723
    increase in cardiac output, 722–723
    negative view, **709–730**
    PAC monitoring of, 721–722
  induced, in vasospasm, 701
Hypervolemia, hypertension, and hemodilution, 701–703
  in cerebral ischemia, 699–700

Hypoperfusion, oxygen deficit due to, tonometry's sensitivity and specificity for, 592–593
Hypoxemia, arterial, causes, 604
patent foramen ovale and, 299–301
Hypoxia, assessment, tonometry in, 593–594
tissue, P_{CO_2}, 1008

ICU. See *Intensive care unit.*
Imminent, 8
Indicator dilution techniques, for cardiac output, 941
Individualism, rise of, in physician–patient relationship, 180–184
Induction, in critical care computing, 110–112
Infection, pulmonary, ventilator-induced, 605
Inflammation, systemic, in critically ill patients, 670–671
Inflammatory disease, of the aorta, 735–736
Informed consent, critique of, 186–191
in physician–patient relationship, 184–185
Inotropic agents, for shock, 963
Integrated scattering, automatic border detection by, 473–478
Intensive care unit (ICU), closed unit, features, advantages, and disadvantages, 526–527
full-time specialist care in, argument against use of, **537–548**
error and negligence, effect on outcome, 546–547
efficiency effects, **525–537**
admissions and discharge criteria, 536
antibiotic costs, 531–532
data supporting, 540–543
hospital charges, 529–531
invasive monitoring, 536
length of stay issue, 529–531
nosocomial pneumonia, 533–534
nutritional management, 535
satisfaction surveys, 536
sedation and paralytic agents, 532–533
ventilator management, 533–534
monitoring in, 1031–1032
goals of, 569
open unit, features, advantages, and disadvantages, 526–527
optimal utilization of, effect on implementation of full-time intensivists, 544–546
organization and staffing of, current status of, 538–540
services of, 778
staffing of, managed care effects on, 548
TEE in, 902–903
transitional unit, characteristics, 527
Intensive care unit (ICU) scoring systems, in prediction of patient outcome, affirmative view, **503–514**
and individual patient decisions, 509–511
historical overview, 515–517
models of, 504–507
negative view, **515–523**
specific scoring systems, 519–521
principles of, 504
in prediction of patient performance, 507–509
Intensivists, ICU, full-time, **525–537.** See also *Intensive care unit (ICU), full-time specialist care in.*
Intimal tears, localization of, echocardiography in aortic dissection for detection of, 753–754
Intracardiac masses, TEE in, 898–899
Intracardiac shunt, **295–319**
atrial septal defects, 301–305
described, 295
fistulas, 308–313
patent foramen ovale, 295–301
sinus of Valsalva aneurysm rupture and, 308–310
sites, 295
TEE in, 901–902
types, 296
ventricular septal defects, 306–308
Intrathoracic pressures, PEEP effects on, 842–848
Intravascular ultrasound, **451–470**
applications, 461–466
future directions, 466
image quality with, determinants of, 454
image quantitation, 459–461
instrumentation in, 452–454
interpretation, 454–461
limitations, 459–461
of arteries and veins, 454–457
of atherosclerotic plaque, 457–459
uses, as diagnostic adjunct, 462–465
in interventional procedures, 461–462
validation, 454–461
Invasive monitoring, complications, in prediction of ICU efficiency with full-time intensivists, 536
Inverse I:E ratio ventilation (IRV), in prevention of VILI, 618–619
Ionescu-Shiley valve, assessment, TEE in, 390
Ischemia, cerebral, hypervolemia and hemodilution in, 699–700
mucosal, assessment, tonometry in, 595–597

Ischemia *(Continued)*
pHi as predictor of, 1010
Isogravimetric technique, for measuring capillary hydrostatic pressure, 823–826

Justice, 136

Kevorkian, 5
Krebs cycle, generation of energy via, 1033–1035

Lactate, survival related to, 640–641
Language of death, **1–14**
Left atrial pressure, PEEP effects on, 852–853
Left ventricular function, assessment, TEE in, **253–272**
afterload assessment, 263–265
cardiac output determination, 260–261
diastolic function, 255–258
global systolic function, 258–260
preload assessment, 254–255
pulmonary venous flow pattern, 255–257
regional left ventricular function, 261–263
transmittal flow patterns, 257–258
PEEP effects on, 853–855
regional, assessment, TEE in, 261–263
Left ventricular volume, assessment, TEE in, 254–255
Length of stay, in prediction of ICU efficiency with full-time intensivists, 529–531
Life threatening, defined, 159
Linear withdrawal, in data acquisition for three-dimensional imaging, 480–481
Lipid(s), in critically ill patients, 673–674
Living donation, 39–40
Living wills, ethics of, 191–192
Low tidal volume, volume-controlled ventilation, in prevention of VILI, 619
Low-rate intermittent mandatory ventilation (IMV), in prevention of VILI, 617–618
Lung salvage surgery, pulmonary artery catheter in goal-directed hemodynamic therapy for, 787

Magnetic resonance imaging (MRI), in cardiac function evaluation, 922–927
Marfan's syndrome, aortic aneurysm due to, 734
Mathematical coupling, flow dependency and, 636–638
of shared measurement error, 978–983
Mechanical transducers, 453
Mechanical ventilation, preload assessment during, 807–809
Medical decision making, ethical, in ICU, **71–84.** See also under *Ethic(s).*
ethics and, relationship between, 73
Medical ethics, as sustained inquiry, 72
Medical futility, **165–178.** See also *Futility.*
and rationing, 174–177
communication in, 170–177
patient autonomy and patient rights, 168–170
prevention, 171
resolving of, 170–177
elimination of confusion and mistrust in, 173–174
goal-focused rather than treatment-focused planning, 171–173
providing adequate information, 173
Medical Nemesis, 98
Medical Power and Medical Ethics, 98
Medically indicated, defined, 159
Medicine, evidence-based, emphasis of, 779
MEDLINE, search of, in diagnostic monitoring strategy, 780
Medtronic-Hall prosthesis, TEE in, 386–389
Membrane(s), TEE imaging and, 244, 245
Microbarotrauma, ventilator-induced, 613–615
Ministers, parish, hospital, roles of, 16
Mistrust, medical futility due to, 173–174
Mitral prostheses, assessment, TEE in, 397–400
Mitral regurgitation, 335–352
assessment, Doppler echocardiography in, 339–344
echocardiography in, two-dimensional, 337–344
described, 335–336
treatment, 344–352
Mitral stenosis, 323–335
assessment, Doppler echocardiography, 328–330
echocardiography in, 324–327
described, 323–324
treatment, 333–335
Mitral valve, assessment, deviation of pressure half-time, 331
described, 322–323
function of, 321–322
regurgitation due to, 335–352. See also *Mitral regurgitation.*
stenosis of, 323–335. See also *Mitral stenosis.*
TEE of, 321–352
Mixed venous oxygen saturation (SVo_2), clinical determinants of, 797

monitoring of, 795
continuous, technology of, 798
Monitoring, goals of, 778, 796
history of, 795–796
in ICU, 1031–1032
in shock patients, 940
invasive hemodynamic, in shock, 941–959
oxygen transport, in shock, 941–959
Moral development, nurses, 125–126
theories of, 124–126
Mortality prediction model (MPM), in ICU scoring systems effectiveness, 505
Mortality probability model (MPM), in ICU scoring systems effectiveness, 516–517
Mucosal ischemia, pHi as predictor of, 1010
Multicomponent noninvasive circulatory monitoring, in shock, 960–961
Murder, 6–7
Myocardial infarction, pulmonary artery catheter in goal-directed hemodynamic therapy for, 788
ventricular septal defects in, 306

Near-infrared spectroscopy, **1019–1029**
applications of, 1026–1027
blood flow measurement using, 1025–1026
equipment, algorithms, and validation of, 1022–1024
future developments in, 1027
technical factors affecting, 1024–1025
theory of, 1021–1022
Neonates, critical care for, ethical issues related to, **149–164**
best interest standard, 153–161
conflicts between children, 157–158
rational parent standard, 153–156
sacrifice of a twin, 157
surrogacy, 153–161
Netherlands, euthanasia in, **97–108.** See also *Euthanasia, in the Netherlands.*
Noninvasive monitoring, early, 961–962
multicomponent, 960–961
Nonmaleficence, 135
Nosocomial pneumonia, in prediction of ICU efficiency with full-time intensivists, 533–534
Nuclear techniques, in cardiac function evaluation, 920–922
Nurse, critical care, ethical dilemmas facing, **123–133.** See also *Ethical issues, facing critical care nurses.*
moral development of, 125–126
Nutrient(s), in critically ill patients, 672–674
Nutrition, enteral, in critically ill patients, 668–669, 672–673
parenteral, in critically ill patients, 668
Nutritional support, in critically ill patients, affirmative view, **661–666**
appetite suppression, 672
clinical outcome, 667–671
enteral nutrition, 668–669, 672–673
glucose intake, 673
guidelines, 661
in burn injuries, 670
in postoperative patients, 668–670
in prediction of ICU efficiency with full-time intensivists, 535
in systemic inflammation and sepsis, 670–671
lipid intake, 673–674
negative view, **667–676**
parenteral nutrition, 668
versus enteral nutrition, 669
reasons for, 664–665
recommendations, 661
risk factors in, 661–663
timing of, 663–664

O_2ER, 998
O_2ER diagram, 999–1001
Oblique sinus, TEE of, 246
Oncotic pressure, and pulmonary edema, 822–823
Optex Biomedical biosentry sensor, in ABG measurements, 872
Optical sensors, in ABG measurements, 867–868
Organ donation, consent in, in organ procurement process, 35–36
increasing, 37–38
contraindications to, 33
determination of death and, 32
elective ventilation, 40
increasing donor pool in, 38–39
living donation, 39–40
prevalence of, 29–30
Organ donors, identification of, in organ procurement process, 33
increase in, in organ procurement process, 38–39
living, ethical issues related to, 158
non–heart-beating, 40–42
Organ failure, and shock, mediators of, relation of tissue hypoxia to, 956
relationship to oxygen debt, 954–956
Organ procurement, 26. See also under *Organ donation.*
ethical issues in, **29–48**
increase in, controversial proposals for, 37–42
obtaining organs for, 29–30

Organ procurement *(Continued)*
organ donation in, controversial proposals for, 37–42
process of, 33–36
asking family to donate, 33–35
consent to donation in, 35–36
donor identification in, 33
organ retrieval in, 36–37
public policy related to, 30–32
Organ retrieval, in organ procurement process, 36–37
Oximetric catheters, versus pulmonary artery catheters, in goal-directed hemodynamic therapy, 789
Oximetry, dual, 798
mixed venous, 796–799
Oxygen consumption, by independent methods, oxygen delivery and, 983–986
in critically ill patients, 646–655
oxygen delivery and, clinical approach, 988–990
versus cardiac index and oxygen extraction ratio, **995–1006**
supporting pathologic dependence of V_{O_2} on D_{O_2}, 976–978
Oxygen consumption/oxygen delivery model, 972–974
Oxygen debt, estimation of, method for, 953–954
mortality related to, 639–640
relationship to organ failure and death, 954–956
Oxygen delivery, **971–994**
and oxygen consumption, versus cardiac index and oxygen extraction ratio, **995–1006**
and oxygen consumption by independent methods, evaluation, 983–986
and oxygen consumption in critical illness, clinical approach, 988–990
clinical applications in, 1001–1004
in critically ill patients, 646–655
increase in, outcome effects of, affirmative view, **635–644**
distribution problem, 641–642
flow dependency and mathematical coupling, 636–638
negative view, **645–659**
randomized controlled trials, 655–657
recommendations, 657
responders versus nonresponders, 638–639
survival, 636
pathologic dependence of oxygen consumption on, 974–976
supporting pathologic dependence of V_{O_2} on D_{O_2}, 976–978
Oxygen extraction ratio, oxygen delivery and consumption versus, **995–1006**
Oxygen metabolism, circulatory function related to, 952–953
in shock, **939–969**
Oxygen supply, and utilization relationship, 972–976
Oxygen toxicity, VILI due to, 606
Oxygen transport, data from, interpretation of, 798–799
defined, 796–797
in shock, **939–969**
monitoring of, in shock, 941–959
patterns of, in surgical patients, 944
terminology related to, 797
variables in, physiologic significance of, 952
Oxygen transport balance, 796–797
Oxyhemoglobin saturation, 866

Pa_{CO_2}, measurement of, 865–866
Palliative Support Care Orders form, 65
Pa_{O_2}, measurement of, 866
Paradoxical embolism, stroke due to, patent foramen ovale and, 298–299
Parallel slicing, in data acquisition for three-dimensional imaging, 480–481
Paralytic agents, in prediction of ICU efficiency with full-time intensivists, 532–533
Parenteral nutrition, in critically ill patients, 668
Parish ministers, roles of, 16
Patent foramen ovale, 295–301
assessment, contrast studies in, 296–298
TEE in, 282–283
hypoxemia due to, 299–301
paradoxical embolism, 298–299
TEE in, 900–901
Patient autonomy, and medical futility, 168–170
Patient decisions, family objections to, 24
staff objections to, 22–23
Patient rights, and medical futility, 168–170
positive versus negative, 169–170
Pcap, See *Pulmonary capillary pressure (Pcap)*
P_{CO_2}, tissue, as marker of tissue hypoxia, 1008
PCWP. See *Pulmonary capillary wedge pressure (PCWP).*
PEEP. See *Positive end-expiratory pressure (PEEP).*
Percutaneous balloon mitral valvuloplasty, in left atrial thrombus assessment, 276–277
Percutaneous balloon valvulotomy, for mitral stenosis, 333–334
Pericardial bioprostheses, assessment, TEE in, 390

Pericardial effusion, TEE in, 885–886
Pfizer Paratrend 7 sensor, in ABG measurements, 872
pH, measurement of, 865
pHi, as index of resuscitation, 1012–1015
  as predictor of morbidity, 1010–1011
  as predictor of mortality, 1011–1012
  as predictor of mucosal ischemia, 1010
Physician(s), leadership role of, in death, 2
Physician comfort, in ethical medical decision making, 74–75
Physician confidentiality, in critical care computing, 119–120
Physician responsibilities, in ICU, philosophic reflection on, 71–72
Physician-assisted suicide, 5–6
Physician–patient relationship, autonomy and, 184–185
  bioethics movement, 185–186
  building of sharing relationships, 194–195
  ethics in, **179–197**
  informed consent and, 184–185
  informed consent in, critique of, 186–191
  living wills and, 191–192
  rise of individualism in, 180–184
  shared decision making in, 192–194
Pneumonia, nosocomial, in prediction of ICU efficiency with full-time intensivists, 533–534
Porcine bioprostheses, assessment, TEE in, 390
Positive end-expiratory pressure (PEEP), effect on interpretation of hemodynamic monitoring, 855–861
  effect on intrathoracic pressures, 842–848
  effect on left ventricular function, 853–855
  effect on pulmonary venous return and left atrial pressure, 852–853
  effect on right atrial and right ventricular filling, 848–849
  effect on right ventricular afterload, 850–852
  extrapulmonary effects, 632–633
  hemodynamic measurements during, **841–864**
Preload, assessment, 806–807
  during mechanical ventilation, 807–809
  TEE in, 880–881
Pressure gradients, in atrial septal defect evaluation, 303–305
Pressure half-time, deviation of, in mitral stenosis assessment, 331
Pressure support ventilation (PSV), in prevention of VILI, 618
Pressure tracing, Pcap, application of template or ruler to, 830–832
Pressure transient, Pcap, analysis of, 830
Pressure-controlled ventilation (PCV), in prevention of VILI, 618
Privacy, in critical care computing, 116–120
Prosthesis(es). See also specific types, e.g., *Aortic prostheses.*
Prosthetic heart valve, aortic, assessment, TEE in, 392–397
  assessment, echocardiographic, Doppler, 391–400
  TEE in, **383–409**
    described, 383–385
  bileaflet type, TEE in, 386–389
  complications, 401–405
  caged-ball type, TEE in, 389
  mechanical prostheses, TEE in, 386–389
  mitral, assessment, TEE in, 397–400
  regurgitation, 390–391
  St. Jude valve, 386–388
  tilting single disc type, TEE in, 386–389
  tissue valves, TEE in, 389–390
Prosthetic regurgitation, pathologic, 390–391
Prosthetic valve infectious endocarditis, assessment, TEE in, 416–417
Pseudomasses, TEE imaging and, 238–243
Pulmonary artery catheter, **777–794**
  annual sales of, 772
  benefits of, 774
    assessment, 771
  clinical scenario, 777–778
    response to, 779
  complications, 774
  criteria for use, 560
  evidence-based recommendations for, 790–791
  future developments in, 813–814
  impact on outcome in critical care, 771
  in mixed ICU patients, 790
  negative or no impact on outcome, studies of, 783
  new, **795–818**
  outcome affected by, affirmative view, **553–557**
  negative view, **559–568**
    data problems, 561–565
      accuracy, 561–563
      application problems, 564–565
      interpretability of, 563–564
    insertion difficulties, 560–561
  positive impact on outcome, studies of, 782
  priorities in, 799–801
  search strategy, 779–780
    cardiac surgery, 787–788
    goal-oriented hemodynamic therapy, 781–786
    hip fracture, 786
    levels of evidence, assigned, 780–781
    literature in, validity of, 780
    myocardial infarction, 788
    results, 781

Pulmonary artery catheter *(Continued)*
selected studies, findings, and levels of evidence, 781–790
vascular surgery, 786–787
uses, 771–773
versus oximetric catheters, in goal-directed hemodynamic therapy, 789
Pulmonary artery occlusion pressure(s), interpretation of, PEEP effects on, 856–861
Pulmonary artery occlusion pressure profile, 832–833
Pulmonary capillary pressure (Pcap), and PCWP difference, clinical studies and clinical implications, 833–836
as bedside measurement, 836–837
clinical implications, **819–839**
history of, 820
measurement of, double occlusion technique, 826
in animals, 823–833
in humans, 832–833
isogravimetric technique, 823–826
problems related to, 836
pulmonary edema and, 820–823
Pulmonary capillary wedge pressure (PCWP), and Pcap, clinical studies and clinical implications, 833–836
in sepsis, 833–835
to measure Pcap, 820
Pulmonary edema, oncotic pressure and, 822–823
Pcap and, 820–823
Pulmonary embolism, assessment, TEE in, 285–287
TEE in, 895–896
Pulmonary infection, ventilator-induced, 605
Pulmonary vasculature, electrical model of, 827–828
Pulmonary venous return, PEEP effects on, 852–853
Puritan Bennett FoxS sensor, in ABG measurements, 871–872

Quinlan, 49
Quinlan, K.A., 137

Radionuclide(s), in cardiac function evaluation, 920–922
Radionuclide angiography (RNA), in cardiac function evaluation, 920–922
Rational parent standard, ethical issues related to, 153–156
Regional function, TEE in, 881–882
Regurgitant jets, TEE and, 248
Regurgitation, aortic. See *Aortic regurgitation.*
Remmelink Committee, 99–100
Remmelink Report, 100–107
Renal failure, acute, dopamine and, 688–690
Resuscitation, duration of, ethics of, 143–145
ethics of, **135–148**
determining level of treatment at admission, 139–140
index of, pHi as, 1012–1015
inpatient, and presumption of consent, 136–140
removal of, 139
out-of-hospital, 140–143
criteria for, ethical, 142–143
legal, 141
medical, 141
Reverberation, TEE and, 248–249
Right atrial filling, PEEP effects on, 848–849
Right atrial pressure, interpretation of, PEEP effects on, 855–856
Right heart function, monitoring of, 801–810
Right ventricular afterload, PEEP effects on, 850–852
Right ventricular ejection fraction, and continuous cardiac output, **795–818**
measurement of, technology of, 802–804
Right ventricular end-diastolic volume, 804–806
Right ventricular filling, PEEP effects on, 848–849
Right ventricular pressure, interpretation of, PEEP effects on, 855–856
Right-heart function, measurements of, concerns regarding, 809–810
Rotational scanning, in data acquisition for three-dimensional imaging, 481

Satisfaction surveys, in prediction of ICU efficiency with full-time intensivists, 536
Search strategy, in diagnostic monitoring strategy, 780
Sedation, in prediction of ICU efficiency with full-time intensivists, 532–533
Sepsis, in critically ill patients, 670–671
PCWP in, 833–835
Septic shock, measurement of, 945–946
survivor and nonsurvivor patterns in, 945–946
Shock, conventional monitoring in, 940
described, 939
invasive hemodynamic monitoring in, 941–959

mortality due to, 939
noninvasive physiologic monitoring in, 959–962
organ failure and, mediators of, relation of tissue hypoxia to, 956
oxygen transport and oxygen metabolism in, **939–969**
oxygen transport monitoring in, 941–959
postoperative, D_{O_2} and V_{O_2} patterns in, 944
septic, measurement of, 945–946
survivor and nonsurvivor patterns in, 945–946
signs of, 939–940
time relationships in, 942
tissue perfusion in, 940–941
treatment, 962–966
algorithm in, 965–966
alpha blocking agents, 963–964
approach to, 964
fluids and transfusions, 962
goals of, 963
inotropic agents, 963
proposed plan, 964–965
vasodilators, 963–964
vasopressors, 963
types, D_{O_2} and V_{O_2} relationship in, 956
Shunt(s), intracardiac, **295–319.** See also *Intracardiac shunt.*
types, 296
Simplified acute physiology score (SAPS), in ICU scoring systems effectiveness, 505–506, 516–517
Sinus(es), oblique, TEE of, 246
transverse, TEE of, 246, 247
Sinus of Valsalva aneurysm, rupture of, shunt due to, 308–310
Spectroscopy, near infrared, **1019–1029.** See also *Near-infrared spectroscopy.*
Spiritual issues, in ICU, **15–27**
bioethics committee in, 21
chaplain and, 16–21. See also *Chaplain, hospital.*
hospital culture and, 15–16
hospital without a staff chaplain, 16–17
organ procurement, 26
parish ministers and, 16
St. Jude valve, assessment, TEE in, 386–388
Starling equation, 819
Statistics, in critical care computing, 111–112
Stress echocardiography, **429–436,** 882–883
Stroke, mortality due to, 273
Subarachnoid hemorrhage (SAH), aneurysmal, hypertension, hypervolemic, hemodilutional therapy for, affirmative view, **697–707**
negative view, **709–730**
Suicide, physician-assisted, 5–6
Supernormal oxygen delivery, randomized control trials of, 986–988
Surrogacy, in neonatal and pediatric critical care, 153–161
Suture(s), TEE of, 243, 244
SV_{O_2}, 997
SV_{O_2}. See *Mixed venous oxygen saturation.*
Swan-Ganz catheter, **771–776.** See also *Pulmonary artery catheter.*

Tamponade, pericardial effusion and, TEE in, 885–886
TEE. See *Transesophageal echocardiography (TEE).*
Thermal injuries, in critically ill patients, 670
Thermal safety, with TEE, 237
Thermodilution techniques, for cardiac output, 941
Thrombus, left atrial, assessment, spontaneous contrast in, 277–278
TEE in, 274–277
left ventricular, assessment, TEE in, 278–279
Tissue energetics, changes in, during pathologic processes, 1038–1040
measurement of, methods of, 1035–1036
Tissue hypoxia, P_{CO_2}, 1008
Tissue perfusion, in shock, 940–941
indexes of, 1004–1005
Tissue valves, assessment, TEE in, 389–390
Tonometry, **1007–1018**
defined, 588
gastric, abnormalities detected by, affirmative view, 574–576
affirmative view, **569–585**
goals of monitoring, 569–571
clinical applications of, 1009–1015
clinical development of, 1008–1009
described, 580, 587
disadvantages, 580–582
monitoring in therapy guided by, affirmative view, 578–580
necessity of, 569–571
negative view, **587–601**
parameters measured by, 589–594
principles of, 588–589
prognosis detected by, affirmative view, 576–578
reasons for, 574
what does it measure, 571–574
technical advances in, 1015–1016
Trachea, air-filled, as factor in TEE imaging, 237
Transducer(s), types, 453
Transesophageal echocardiography (TEE), **875–918**
aortic diseases, 887–891
benefits of, 886–887
biplane, single-plane, multiplane and, comparison among, 206

Transesophageal echocardiography (TEE) *(Continued)*
color-flow Doppler imaging versus, 247–250
computer technologies and, 884–885
contraindications, 876
critical appraisal of, **235–251.** See also *Transesophageal echocardiography (TEE), limitations.*
described, 204
in assessment of embolic sources, **273–294**
atherosclerotic aortic debris, 284–285
atrial fibrillation, 275–276
atrial septal aneurysm, 283–284
intracardiac tumors, 280–282
left atrial thrombus, 274–277
left ventricular thrombus, 278–279
patent foramen ovale, 282–283
pulmonary embolism, 285–287
systemic embolism, 274–285
vegetation, 279–280
in assessment of left ventricular function, **253–272.** See also *Left ventricular function, assessment, TEE in.*
in assessment of valvular heart disease, **321–381.** See also specific valve, e.g., *Mitral valve.*
aortic regurgitation, 364–367
aortic stenosis, 354–364
aortic valve, 352–369
mitral regurgitation, 335–352
mitral stenosis, 323–335
mitral valve, 321–352
tricuspid valve, 369–375
in diastolic function, 883–884
in endocarditis, 896–898
in global systolic function, 878–879
in ICU, 902–903
in intracardiac masses, 898–899
in intracardiac shunts, 901–902
in patent foramen ovale, 900–901
in pericardial effusion, 885–886
in preload assessment, 880–881
in prosthetic heart valve assessment, **383–409**
in pulmonary embolism, 895–896
in regional function, 881–882
in valvular heart disease, 891–895
in ventricular performance assessment, 878–887
indications for, 876
limitations, 236
echo-free spaces, 246–247
equipment, 237–238
extracardiac fluid visualization, 249–250
ghosting, 248–249
imaging abilities, 236–237
membranes, 244, 245
pseudomasses, 238–243
regurgitant jets, 248
reverberations, 248–249
safety, 237–238
limitations of, 886–887
multiplane, **203–233**
described, 204
examination with, 205–206, 210–232
applications, 230–232
four-chamber views, 224–225
left atrial appendage and pulmonary vein, 225, 230
limitations, 232
longitudinal plane views, 211, 217–221
thoracic aorta, 230, 232
transgastric views, 224, 225–229
views, 211, 213–216
image notation with, 206–210
image orientation, 207–210
instrumentation, 206–207
patient preparation for, 205–206
setup, 210
single-plane, biplane, and, comparison among, 206
systematic examination with, 210
of aortic valve, 240, 243
of atria, limitations, 238–240
of atrial septum, limitations, 238, 240, 241
of sutures, 243, 244
of tricuspid annulus, 240, 242
risk factors with, 876–877
safety considerations with, 237–238
single-plane, biplane, multiplane and, comparison among, 206
versus TTE, 875
Transplantation. See also *Organ procurement.*
Transthoracic echocardiography (TTE), in abscess detection, 417–418
in infectious endocarditis assessment, 418–420
in pericardial effusion, 885–886
in prosthetic heart valve assessment, 383
in vegetation detection, 414–416
role of, 203–204
versus TEE, 875
Transverse sinus, TEE of, 246, 247
Trauma, aortic, ultrasonic examination, 743–744
severe, survivor and nonsurvivor patterns in, 945
ventricular septal defects in, 306–307
Tricuspid annulus, pseudomasses of, TEE of, 240, 242
Tricuspid valve, TEE of, 369–375
Trust, building of, in resolving medical futility, 174
Tumor(s), intracardiac, assessment, TEE in, 280–282

Twin(s), sacrifice of, ethical issues related to, 157

Ultrasonic tissue characterization of myocardium, 436–437
Ultrasonography, in automatic border detection, 437–440
  intravascular, **451–470.** See also *Intravascular ultrasound.*
  tissue characterization with, 436–437
Uncertainty, in ethical medical decision making, 74
  science of, 3–4

Valve(s). See specific types, e.g., *Mitral valve.*
Valve of fossa ovalis, membranes of, TEE of, 244, 245
Valvular heart disease, assessment, intraoperative, TEE in, **321–381**
  native, TEE in, 891–895
  prosthetic, TEE in, 895
  TEE in, 891–895
Valvuloplasty, percutaneous mitral, in left atrial thrombus assessment, 276–277
Valvulotomy, percutaneous balloon, for mitral stenosis, 333–334
Vascular surgery, pulmonary artery catheter in goal-directed hemodynamic therapy for, 786–787
Vasodilators, for shock, 963–964
Vasopressors, for shock, 963
Vasospasm, induced hypertension in, 701
  pathophysiology, 698–699
Vegetation(s), detection, TEE versus TTE in, 414–416
  in prosthetic valve endocarditis, 401–405
Vein(s), intravascular ultrasound characteristics of, 454–457
Venous resistance, measurement of, 828–830
Ventilation, elective, 40
  intermittent mandatory, low-rate, in prevention of VILI, 617–618
  inverse I:E ratio, in prevention of VILI, 618–619
  low tidal volume mechanical, in prevention of VILI, 619
  lung protective, 630–631
  mechanical, preload assessment during, 807–809
  new modes of, in prevention of VILI, 617–620
  pressure support, in prevention of VILI, 618
  pressure-controlled, in prevention of VILI, 618
Ventilator(s), lung injury due to, **603–625.** See also under *Ventilator-induced lung injury (VILI).*
Ventilator-induced lung injury (VILI), **603–625, 627–634**
  airway complications, 605
  barotrauma, 607–613, 628–630
  clinical relevance of, 616–617
  microbarotrauma, 613–615
  oxygen toxicity, 606
  prevention, ventilatory modes in, 617–620, 630–631
  pulmonary infection, 605
  types, 605–615
  ventilatory muscle atrophy, 606–607
  ventilatory muscle fatigue, 606–607
  volutrauma, 615
Ventilatory management, in prediction of ICU efficiency with full-time intensivists, 533–534
  lung injury due to, affirmative view, **603–625.** See also under *Ventilator-induced lung injury (VILI).*
    negative view, **627–634.** See also under *Ventilator-induced lung injury (VILI).*
Ventilatory muscle fatigue, 606–607
Ventricular septal defects (VSDs), 306–308
  calculation of shunt, 308
  congenital, 308
  diagnosis, 307–308
  myocardial infarction and, 306
  trauma and, 306–307
Ventricular volume, assessment, TEE in, 884–885
VILI. See *Ventilator-induced lung injury (VILI).*
V_{O_2}, 997–998
  determination and relationship in, 998–999
  direct Fick measurements of, in shock, 941
Volutrauma, ventilator-induced, 615

Withdrawal, versus withholding, 7–8
Withholding, versus withdrawal, 7–8